Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir with Chemoradiation in Advanced Cervical Cancer
NCT03256916Phase 3Completed
- Sponsor
- Tata Memorial Hospital
- Start
- Jan 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nelfinavir in Cervical Cancer (CC) (2 arms), sponsored by Tata Memorial Hospital. Primary endpoint: Disease-Free Survival at 3 years. Started Jan 2018; status: completed.
02
Drugs
nelfinavir
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03256916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256916.